                </a></li></ul></div><p><strong>Figure 2.  <span>Immunophenotype of PBMCs from healthy donors and NPC patients.</span></strong></p><a id="article1.body1.sec2.sec1.fig2.caption1.p1" name="article1.body1.sec2.sec1.fig2.caption1.p1"></a><p>Surface markers analysis was performed by directly immunofluorescence labeling and FACS analysis in PBMCs from healthy donors (n = 20) and NPC patients (n = 40). * P&lt;0.01</p>
<span>THISISTHEEND
